Related Experiment Video
Updated: Aug 5, 2026
09:04
Selected Reaction Monitoring Mass Spectrometry for Absolute Protein Quantification
Published on: August 17, 2015
[Quantitative pharmaceutical indicators and reform: do they change when there are no staff changes?]
S Juncosa Font1, M Faixedas Brunsoms, M Condal Elies
1Servicios Sanitarios del Area de Gestión n. 4, Gerona.
Atencion Primaria
|January 1, 1991
Summary
Pharmaceutical indicator trends varied significantly across three reformed healthcare centers (ABS) in Girona post-reform. These differences in prescription amounts and rates highlight the varied impact of healthcare system changes.
Area of Science:
- Health Services Research
- Pharmaceutical Policy
- Healthcare Management
Background:
- Evaluating the impact of healthcare reforms on pharmaceutical utilization is crucial.
- Understanding variations in pharmaceutical indicators within reformed systems is essential for policy adjustments.
Purpose of the Study:
- To assess the evolution of quantitative pharmaceutical indicators in three primary care centers (ABS) in Girona following a healthcare system reformation.
- To compare these changes with non-reformed areas within the same province.
Main Methods:
- A comparative analysis of pharmaceutical indicators (amount/prescription, amount/inhabitant, prescriptions/inhabitant) before and after a specific reformation period.
- Statistical comparison of indicator increments across reformed and non-reformed healthcare settings.
Main Results:
- Significant differences in pharmaceutical indicators emerged post-reformation (p<0.01 for amount/prescription, p=0.01 for amount/inhabitant and prescriptions/inhabitant).
- Pre-reformation indicator trends showed no significant differences among the centers.
- The three reformed ABS exhibited distinct patterns and contributions to the observed indicator variations.
Conclusions:
- Healthcare system reforms can lead to varied evolutions in pharmaceutical indicators, even among centers with similar characteristics.
- Factors beyond the specific healthcare system design appear to influence pharmaceutical indicator trends in the short term.
- Further research is needed to explore the quality of prescriptions and other influencing factors.
Related Concept Videos
01:14Drug Dissolution: Requirements and Profile Comparison
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...